Goodwin Cross-Border Team Advises Heidelberg Pharma In Royalty Financing Agreement With HCRx
March 06, 2024
March 06, 2024
BOSTON, Massachusetts, March 6 -- Goodwin, a law firm, issued the following news release:
A global Goodwin team advised Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), on its royalty financing agreement with Healthcare Royalty (HCRx) for up to $115 million.
Under the agreement, HCRx will acquire Heidelberg Pharma's royalties on sales of Zircaix(TM) (TLX250-CDx), a microdose radiopharmaceutica . . .
A global Goodwin team advised Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), on its royalty financing agreement with Healthcare Royalty (HCRx) for up to $115 million.
Under the agreement, HCRx will acquire Heidelberg Pharma's royalties on sales of Zircaix(TM) (TLX250-CDx), a microdose radiopharmaceutica . . .